FDA-Approved Medications for Bipolar I Disorder with Psychotic Features
For adults with Bipolar I disorder experiencing acute manic or mixed episodes with psychotic features, use lithium, valproate, or an atypical antipsychotic (aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone, asenapine, or cariprazine) as first-line monotherapy, with atypical antipsychotics being particularly advantageous when psychotic symptoms are prominent.
FDA-Approved Medications for Acute Mania
The following medications have FDA approval for acute manic episodes in adults 1:
Mood Stabilizers
- Lithium - approved for acute mania and maintenance therapy
- Valproate (divalproex) - approved for acute mania
Atypical Antipsychotics (Second-Generation)
- Aripiprazole
- Olanzapine
- Risperidone
- Quetiapine
- Ziprasidone
- Asenapine
- Cariprazine
Typical Antipsychotics (First-Generation)
- Chlorpromazine - approved but not recommended as first-line due to side effect profile 1
Treatment Algorithm for Bipolar I with Psychosis
When psychotic features are present:
Prioritize atypical antipsychotics as monotherapy - they address both manic symptoms and psychotic features simultaneously 1
Alternative approach: Combine lithium or valproate with an antipsychotic - evidence suggests lower relapse rates when antipsychotic medication is maintained for at least 4 weeks in combination with lithium for acute psychotic mania 1
Avoid monotherapy with mood stabilizers alone when psychosis is prominent - the dual pathology requires antipsychotic coverage
Hierarchical Ranking Based on Recent Evidence
According to the most recent comprehensive guidelines 2, first-line treatments for acute mania in hierarchical order include:
- Lithium (highest ranking for overall bipolar treatment)
- Quetiapine
- Divalproex
- Asenapine
- Aripiprazole
- Paliperidone
- Risperidone
- Cariprazine
Key Clinical Considerations
Medication selection should prioritize:
Efficacy for psychotic symptoms - atypical antipsychotics have superior antipsychotic properties compared to mood stabilizers alone 1
Side effect profile - newer atypical antipsychotics (lurasidone, brexpiprazole, cariprazine) were developed to reduce metabolic and cardiovascular side effects, though weight gain remains a concern with some agents 3
Speed of response - atypical antipsychotics typically provide faster control of agitation and psychotic symptoms than mood stabilizers 4
Specific Agent Profiles
Olanzapine: Superior efficacy data for acute mania with psychosis, but highest weight gain risk 5. Also approved for maintenance therapy 1.
Quetiapine: Broad-spectrum efficacy across manic and depressive poles, moderate metabolic concerns 2, 6.
Aripiprazole: Lower metabolic risk, but higher akathisia rates 3. Available in long-acting injectable formulations for maintenance 7.
Cariprazine: Newer agent with full-spectrum efficacy (approved for both manic and depressive episodes), lower rates of mood events compared to aripiprazole in real-world data 8, 6.
Risperidone: Well-established efficacy, moderate metabolic concerns 2.
Common Pitfalls to Avoid
Do not use antidepressants as monotherapy - they can destabilize mood and induce switching to mania or mixed episodes 1
Avoid gabapentin and topiramate - controlled studies show they are not effective for bipolar mania 1
Reserve clozapine for treatment-refractory cases only due to its side effect profile and monitoring requirements 1
Do not discontinue antipsychotics prematurely - maintain for at least 4 weeks in combination therapy for psychotic mania to prevent relapse 1
Maintenance Considerations
Once acute symptoms are controlled, FDA-approved maintenance options include 1:
- Lithium
- Lamotrigine
- Olanzapine
- Aripiprazole (including long-acting injectable)
- Quetiapine
- Asenapine
Continue the medication that successfully treated the acute episode for maintenance therapy, as this approach is associated with better outcomes 2, 6.